Celgene cost-sharing deal sways NICE to greenlight new Revlimid use

Celgene ($CELG) used a tried-and-true technique to persuade cost-effectiveness watchdogs to change their minds on a new use for Revlimid. The U.S.-based drugmaker capped its cost. Could this sort of cost-sharing deal help payers wrangle with other pricey meds? Report

 

Suggested Articles

A self-proclaimed former employee at Novartis’ Beijing office accused the Swiss drugmaker of expensing fake academic events to offer kickbacks to doctors.

Novo Nordisk just won an FDA approval that could help it stand out in the crowded—and competitive—basal insulin category.

Pfizer is training pharmacists in the U.K. to handle over-the-counter Viagra.